Caspofungin MICs Correlate with Treatment Outcomes among Patients with Candida glabrata Invasive Candidiasis and Prior Echinocandin Exposure

Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

(2013) Barbara D. Alexander et al.   CLINICAL INFECTIOUS DISEASES

Caspofungin Etest Susceptibility Testing of Candida Species: Risk of Misclassification of Susceptible Isolates of C. glabrata and C. krusei when Adopting the Revised CLSI Caspofungin Breakpoints

(2012) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Optimizing Echinocandin Dosing and Susceptibility Breakpoint Determination viaIn VivoPharmacodynamic Evaluation against Candida glabrata with and withoutfksMutations

(2012) Alexander Lepak et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Presence of anFKSMutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata

(2012) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials

(2012) D. R. Andes et al.   CLINICAL INFECTIOUS DISEASES

Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study

(2012) G. A. Eschenauer et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of Dimethyl Sulfoxide and Water as Solvents for Echinocandin Susceptibility Testing by the EUCAST Methodology

(2012) A. Alastruey-Izquierdo et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Species Identification and Antifungal Susceptibility Testing of Candida Bloodstream Isolates from Population-Based Surveillance Studies in Two U.S. Cities from 2008 to 2011

(2012) S. R. Lockhart et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012

(2012) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Echinocandin Susceptibility Testing ofCandidaspp. Using EUCAST EDef 7.1 and CLSI M27-A3 Standard Procedures: Analysis of the Influence of Bovine Serum Albumin Supplementation, Storage Time, and Drug Lots

(2011) Maiken Cavling Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria

(2011) M.A. Pfaller et al.   DRUG RESISTANCE UPDATES

Breakthrough Invasive Candidiasis in Patients on Micafungin

(2010) C. D. Pfeiffer et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Echinocandin Susceptibility Testing of Candida Species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, Disk Diffusion, and Agar Dilution Methods with RPMI and IsoSensitest Media

(2009) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3- -D-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint

(2009) G. Garcia-Effron et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America

(2009) Peter G. Pappas et al.   CLINICAL INFECTIOUS DISEASES

Wild-Type MIC Distributions and Epidemiological Cutoff Values for the Echinocandins andCandidaspp.

(2009) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Mutations in the fks1 Gene in Candida albicans, C. tropicalis, and C. krusei Correlate with Elevated Caspofungin MICs Uncovered in AM3 Medium Using the Method of the European Committee on Antibiotic Susceptibility Testing

(2008) M. Desnos-Ollivier et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Breakthrough Aspergillus fumigatus and Candida albicans Double Infection during Caspofungin Treatment: Laboratory Characteristics and Implication for Susceptibility Testing

(2008) M. C. Arendrup et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

(2008) Brahm H. Segal et al.   CLINICAL INFECTIOUS DISEASES

EUCAST Definitive Document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts

(2008) J.L. Rodriguez-Tudela et al.   CLINICAL MICROBIOLOGY AND INFECTION

Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC Breakpoints

(2008) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Detection of Caspofungin Resistance in Candida spp. by Etest

(2008) M. Desnos-Ollivier et al.   JOURNAL OF CLINICAL MICROBIOLOGY

McNemar χ2test revisited: comparing sensitivity and specificity of diagnostic examinations

(2008) A. Trajman et al.   SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION